New Frontiers in Therapeutics for Interstitial Lung Diseases
- 15 April 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (8) , 1089-1091
Abstract
No abstract availableFunding Information
- National Heart, Lung, and Blood Institute (T32 HL007035)
- National Heart, Lung, and Blood Institute (T32 HL007035)
This publication has 21 references indexed in Scilit:
- The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Diagnosis and management of interstitial lung diseaseTranslational Respiratory Medicine, 2014
- Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trialThorax, 2012
- Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3American Journal of Respiratory and Critical Care Medicine, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibitionLung India, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003